CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Cystagon (cysteamine) for nephropathic cystinosis — Coverage Criteria

Policy governs prior authorization, documentation, and coverage criteria for Cystagon when used to manage nephropathic cystinosis for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCystagon (cysteamine) for nephropathic cystinosis — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain assay showing increased leukocyte cystine concentration or genetic testing to confirm diagnosis before initial authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization period for initial therapy

12 monthsauthorization period for continuation therapy

FDA-approvedindication: nephropathic cystinosis

Not coveredother uses

Coverage Criteria

Initial therapy

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCystagon (cysteamine) for nephropathic cystinosis — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain assay showing increased leukocyte cystine concentration or genetic testing to confirm diagnosis before initial authorization.

SourceLink

On This Page

Diagnosis of nephropathic cystinosis confirmed by increased leukocyte cystine concentration assay or by genetic testing.

See required documentation for initial requests.

Concomitant therapy: Member will not use Cystagon in combination with Procysbi.

Concomitant use with Procysbi is a disqualifying factor for authorization.

Authorization period: Authorization may be granted for up to 12 months for initial therapy when criteria are met.12 months

Prior authorization duration is 12 months.

Continuation therapy

Covered when ALL of the following are met

Response to therapy: Member is responding to therapy, as evidenced by improvement, stabilization, or slowing of disease progression in serum creatinine, calculated creatinine clearance, or leukocyte cystine concentration; maintained growth (height) may also be used in pediatric patients.

Document response with lab results or chart notes.

Absence of contraindicated concomitant therapy: Member will not use Cystagon in combination with Procysbi.

Concurrent use with Procysbi remains disqualifying for continuation authorization.

Authorization period: Authorization for continued treatment may be granted for up to 12 months when criteria are met.12 months

Prior authorization duration is 12 months for continuation requests.

Provider Actions & Authorization Requirements

Prior Authorization

Prior Authorization Duration

Prior authorization required. Authorization may be granted for up to 12 months for initial and continuation therapy when all criteria are met.

Authorization duration: up to 12 months for both initial and continuation requests when criteria are satisfied.

Documentation Required

Initial Request Requirements

Initial request requirements. Diagnosis must be confirmed by a leukocyte cystine assay showing increased cystine concentration or by genetic testing. Include diagnostic reports and relevant clinical documentation with the initial authorization request.

Required diagnostic confirmation: leukocyte cystine assay OR genetic testing results supporting diagnosis of nephropathic cystinosis.
Include assay reports or genetic testing documentation with the initial prior authorization request.

Denial Risk

Concomitant Therapy Restriction

Concomitant therapy restriction. Member must not be taking Cystagon in combination with Procysbi to qualify for authorization.

Requests for members using Cystagon concurrently with Procysbi will not meet authorization criteria.

Documentation Required

Required Documentation

Required documentation. Provide the following documents with initial and continuation requests to support medical necessity determinations.

Initial requests: leukocyte cystine assay results showing increased cystine concentration OR genetic testing results confirming cystinosis; relevant clinical notes summarizing presentation and rationale for therapy.
Continuation requests: recent lab results or chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression assessed by serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth/height).
Include medication history and evidence that the member is not taking Cystagon with Procysbi.

Note

Non‑approved Indications

Non‑approved indications. Cystagon is FDA‑approved for nephropathic cystinosis only. Requests for other indications are considered experimental/investigational and are not medically necessary.

Only nephropathic cystinosis (FDA‑approved indication) is covered; all other indications are non‑covered/experimental.

Definitions

Confirmed diagnosis of nephropathic cystinosis

Diagnostic test — leukocyte cystine concentrationPresence of increased cystine concentration in leukocytes detected by assay

Diagnostic test — genetic testingGenetic testing results supporting a diagnosis of cystinosis

Documentation required for initial requestSubmit assay showing increased leukocyte cystine concentration or genetic testing results to initiate prior authorization review

Continuation requirement (related)For reauthorization, documentation of response to therapy (improvement, stabilization, or slowing of disease progression in serum creatinine, calculated creatinine clearance, or leukocyte cystine concentration) may be required

Background

Nephropathic cystinosis is treated with cysteamine (Cystagon), which is indicated to manage this disorder in children and adults by reducing intraleukocyte cystine and slowing progression of renal dysfunction. Treatment response is monitored with measures such as serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, and growth in pediatric patients.